

Marcial Sebode

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4867731/publications.pdf>

Version: 2024-02-01

48
papers

1,739
citations

430843
18
h-index

302107
39
g-index

49
all docs

49
docs citations

49
times ranked

2326
citing authors

#	ARTICLE	IF	CITATIONS
1	Analysis of the humoral and cellular response after <i>the third</i> COVID-19 vaccination in patients with autoimmune hepatitis. Liver International, 2023, 43, 393-400.	3.9	11
2	Quantification of polyreactive immunoglobulin G facilitates the diagnosis of autoimmune hepatitis. Hepatology, 2022, 75, 13-27.	7.3	16
3	Low antibody titers after second SARS-CoV-2 vaccination in patients with autoimmune hepatitis. Zeitschrift Fur Gastroenterologie, 2022, 60, .	0.5	0
4	Autoimmune hepatitis and COVID-19: No increased risk for AIH after vaccination but reduced care. Journal of Hepatology, 2022, 77, 250-251.	3.7	9
5	SARS-CoV-2 vaccination response in patients with autoimmune hepatitis and autoimmune cholestatic liver disease. United European Gastroenterology Journal, 2022, 10, 319-329.	3.8	27
6	Consensus recommendations for histological criteria of autoimmune hepatitis from the International AIH Pathology Group. Liver International, 2022, 42, 1058-1069.	3.9	45
7	Histological spectrum of autoimmune hepatitis”reply to Fujiwara K. et al.. Liver International, 2022, 42, 1704-1705.	3.9	0
8	Inflammatory type 2 conventional dendritic cells contribute to murine and human cholangitis. Journal of Hepatology, 2022, 77, 1532-1544.	3.7	5
9	Reply to: “Both tacrolimus and mycophenylate mophetil should be considered second-line therapy for autoimmune hepatitis” Journal of Hepatology, 2021, 74, 755-756.	3.7	2
10	Prevalence of COVID-19 in patients with autoimmune liver disease in Europe: A patient-oriented online survey. United European Gastroenterology Journal, 2021, 9, 797-808.	3.8	12
11	SARS-CoV-2 infection in patients with autoimmune hepatitis. Journal of Hepatology, 2021, 74, 1335-1343.	3.7	90
12	Genetic aspects of adult and pediatric autoimmune hepatitis: A concise review. European Journal of Medical Genetics, 2021, 64, 104214.	1.3	10
13	Drug-induced liver injury at a tertiary care centre in Germany: Model for end-stage liver disease is the best predictor of outcome. Liver International, 2021, 41, 2383-2395.	3.9	8
14	Single-cell atlas of hepatic T cells reveals expansion of liver-resident naive-like CD4+ T cells in primary sclerosing cholangitis. Journal of Hepatology, 2021, 75, 414-423.	3.7	49
15	One liver, two samples and two diagnoses”An example of how multiple samples by laparoscopically guided liver biopsy can be decisive. Liver International, 2021, 41, 2786-2787.	3.9	0
16	Mobile app requirements for patients with rare liver diseases: A single center survey for the ERN RARE-LIVER. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101760.	1.5	1
17	Perforation of the ascending colon during implantation of an indwelling peritoneal catheter: a case report. BMC Gastroenterology, 2020, 20, 345.	2.0	1
18	Second-line and third-line therapy for autoimmune hepatitis: A position statement from the European Reference Network on Hepatological Diseases and the International Autoimmune Hepatitis Group. Journal of Hepatology, 2020, 73, 1496-1506.	3.7	55

#	ARTICLE	IF	CITATIONS
19	A disease-specific decline of the relative abundance of <i>Bifidobacterium</i> in patients with autoimmune hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1417-1428.	3.7	55
20	Metamizole: An underrated agent causing severe idiosyncratic drug-induced liver injury. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1406-1415.	2.4	23
21	Monocytes as Potential Mediators of Pathogen-Induced T _H 17 Differentiation in Patients With Primary Sclerosing Cholangitis (PSC). <i>Hepatology</i> , 2020, 72, 1310-1326.	7.3	50
22	Features and outcome of AIH patients without elevation of IgG. <i>JHEP Reports</i> , 2020, 2, 100094.	4.9	21
23	Bone microarchitecture in patients with autoimmune hepatitis. <i>Journal of Bone and Mineral Research</i> , 2020, 36, 1316-1325.	2.8	3
24	Population-based study of autoimmune hepatitis and primary biliary cholangitis in Germany: rising prevalences based on ICD codes, yet deficits in medical treatment. <i>Zeitschrift Fur Gastroenterologie</i> , 2020, 58, 431-438.	0.5	17
25	Metamizole Has Been Overlooked as a Trigger for Acute Liver Injury and Acute Liver Failure. <i>Deutsches A&#x0308;rztblatt International</i> , 2020, 117, 610.	0.9	2
26	Sex differences in clinical presentation and prognosis in patients with primary biliary cholangitis. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 1391-1396.	1.5	8
27	TNF-Producing Th1 Cells Are Selectively Expanded in Liver Infiltrates of Patients with Autoimmune Hepatitis. <i>Journal of Immunology</i> , 2019, 203, 3148-3156.	0.8	35
28	The Translational Landscape of the Human Heart. <i>Cell</i> , 2019, 178, 242-260.e29.	28.9	407
29	Inflammatory Phenotype of Intrahepatic Sulfatide-Reactive Type II NKT Cells in Humans With Autoimmune Hepatitis. <i>Frontiers in Immunology</i> , 2019, 10, 1065.	4.8	16
30	Editorial: post-operative elevation of liver enzymes and modern volatile anaesthetics – guilty as charged?. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1245-1246.	3.7	1
31	Autoimmune hepatitis: Is the autoimmunity in the family?. <i>Liver International</i> , 2019, 39, 42-44.	3.9	1
32	Drugs for Soft Tissue Autoimmune Disorders. , 2019, , 751-775.		0
33	Usefulness of biochemical remission and transient elastography in monitoring disease course in autoimmune hepatitis. <i>Journal of Hepatology</i> , 2018, 68, 754-763.	3.7	90
34	Autoimmune hepatitis: From current knowledge and clinical practice to future research agenda. <i>Liver International</i> , 2018, 38, 15-22.	3.9	71
35	Efficacy and Limitations of Budesonide as a Second-Line Treatment for Patients With Autoimmune Hepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 260-267.e1.	4.4	54
36	Variant syndromes of primary biliary cholangitis. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2018, 34-35, 55-61.	2.4	13

#	ARTICLE	IF	CITATIONS
37	Patients with primary biliary cholangitis and fatigue present with depressive symptoms and selected cognitive deficits, but with normal attention performance and brain structure. PLoS ONE, 2018, 13, e0190005.	2.5	11
38	Anti- $\text{TNF-}\alpha$ for necrotizing sarcoid granulomatosis of the liver. Hepatology, 2017, 65, 1410-1412.	7.3	9
39	CD4+ T cells from patients with primary sclerosing cholangitis exhibit reduced apoptosis and down-regulation of proapoptotic Bim in peripheral blood. Journal of Leukocyte Biology, 2017, 101, 589-597.	3.3	15
40	Autoimmune(-Like) Drug and Herb Induced Liver Injury: New Insights into Molecular Pathogenesis. International Journal of Molecular Sciences, 2017, 18, 1954.	4.1	39
41	No Evidence That Azathioprine Increases Risk of Cholangiocarcinoma in Patients With Primary Sclerosing Cholangitis. Clinical Gastroenterology and Hepatology, 2016, 14, 1806-1812.	4.4	15
42	Transient elastography in autoimmune hepatitis: Timing determines the impact of inflammation and fibrosis. Journal of Hepatology, 2016, 65, 769-775.	3.7	127
43	Validation of Transient Elastography and Comparison with Spleen Length Measurement for Staging of Fibrosis and Clinical Prognosis in Primary Sclerosing Cholangitis. PLoS ONE, 2016, 11, e0164224.	2.5	45
44	Natural killer T cells: Novel players in biliary disease?. Hepatology, 2015, 62, 999-1000.	7.3	4
45	Phenotypic alterations of regulatory T cells in autoimmune hepatitis: Causal or associated with treatment and remission?. Hepatology, 2015, 61, 736-737.	7.3	5
46	Patient selection based on treatment duration and liver biochemistry increases success rates after treatment withdrawal in autoimmune hepatitis. Journal of Hepatology, 2015, 62, 642-646.	3.7	82
47	Future Perspective: Immunomodulatory Therapy for Autoimmune Hepatitis. Digestive Diseases, 2014, 32, 502-506.	1.9	5
48	FOXP3+ regulatory T cells in autoimmune hepatitis are fully functional and not reduced in frequency. Journal of Hepatology, 2012, 57, 125-132.	3.7	174